Image
2025 Retreat
WHEN: 8 a.m.-5 p.m. August 19, 2025
WHERE: I Hotel & Conference Center
DEADLINE: Register to attend by Aug. 5.
CONTACT: tanyap2@illinois.edu or dajinc2@illinois.edu
The MCB Graduate Research Retreat brings together researchers from across the school to highlight innovative discoveries and foster meaningful scientific discussions. It’s a great chance to learn about the latest developments in the field and to connect with colleagues in a collaborative environment.
We’re excited to announce that this year’s retreat will feature an impressive 76 presenters, with research spanning departments and labs from across the entire campus!
Schedule
| 8:15 – 8:45 a.m. | Check-in and Continental Breakfast for Registered Attendees – Honors Room |
| 8:45 – 9:00 a.m. | Opening Remarks – Heritage Hall |
| 9:00 – 10:15 a.m. | Session I: Oral Presentations |
| 10:15 – 11:15 a.m. | Session I: Poster Presentations – Heritage Hall |
| 11:15 – 12:00 p.m. | Guest Speaker Talk – Dr. Gene Robinson |
| 12:00 – 1:00 p.m. | Boxed Lunch for Registered Attendees – Heritage Hall |
| 1:00 – 2:15 p.m. | Session II: Oral Presentations – Heritage Hall |
| 2:15 – 3:15 p.m. | Session II: Poster Presentations |
| 3:15 – 4:15 p.m. | Keynote Speaker Presentation – Dr. Michael Recny |
| 4:15 – 5:00 p.m. | Graduate Award Recipient Recognition |
Speakers
Keynote speaker: Dr. Michael A. Recny
Guest speaker: Dr. Gene Robinson
Research Presentations
Coming soon
2025 Keynote and Guest Speakers
Title
Dr. Michael A. Recny
Body
Image
Our keynote speaker will be Illinois alumnus and biotechnology executive Dr. Michael A. Recny (PhD, '83, biochemistry). Dr. Recny is a veteran drug developer with four decades of experience in the biotechnology and contract research organization (CRO) industries. During his career, he made important contributions to the R&D and commercialization of three FDA approved drugs that have collectively sold billions worldwide, and to four other experimental drug candidates that entered human clinical trials.
Dr. Recny most recently served as CEO and a co-owner of Calvert Holdings, Inc., a diversified holding company with subsidiaries that offered non-clinical services and investment opportunities to early-stage biotechnology companies. He also served as CEO of Calvert Laboratories, one of Calvert Holdings wholly owned subsidiaries that conducts FDA regulated laboratory studies for biotechnology companies developing experimental drugs. After selling Calvert Labs to a large multinational CRO in 2021 and dissolving Calvert Holdings in 2023, he continues to serve as President and co-owner of Calvert Research, LLC, an investment company that holds equity positions in private biotechnology companies. Prior to his role as CEO, he was Executive Vice President and Chief Investment Officer for Calvert Holdings where he focused on identifying new business opportunities and sourcing capital to fund new business ventures.
Before joining Calvert Holdings in 2007, Dr. Recny spent 12 years with Trimeris, Inc. (NASDAQ: TRMS; acquired by Alexion, Inc.) as Vice President of Corporate Development where he was a key member of Trimeris’ 1997 internal IPO team. He also made significant contributions to the development and approval of FUZEON®, Trimeris’ first-in-class HIV antiviral therapeutic. Prior to Trimeris, he was Director of Protein Biochemistry at Procept, Inc. (NASDAQ: PRCT; acquired by Interneuron, Inc.), where he structured three collaborative R&D agreements with international pharmaceutical companies over a five-year period.
Earlier in his career, Dr Recny was a Staff Scientist and Laboratory Head at Genetics Institute, Inc. (NASDAQ: GENI; acquired by Pfizer), where his laboratory was the first to report the correct protein structures of both natural and recombinant human erythropoietin. He was a Joseph C. Wilson Scholar at the University of Rochester (1979) and he earned his PhD in Biochemistry from Illinois (1983). Michael and his wife Catherine have two grown children and split their time between homes in Chapel Hill, NC, and on Cape Cod, Mass.
Title
Dr. Gene E. Robinson
Body
Image
Our guest speaker is Dr. Gene E. Robinson, Director of the Carl R. Woese Institute for Genomic Biology at the University of Illinois Urbana-Champaign. Dr. Robinson obtained his PhD from Cornell University in 1986 and joined the Illinois faculty in 1989. In addition to being director at IGB, he holds a University Swanlund Chair and a Center for Advanced Study Professorship and is director of the Bee Research Facility.
Dr. Robinson pioneered the application of genomics to the study of social behavior and founded the subfield of sociogenomics, led the effort to sequence the honey bee genome, authored or co-authored over 350 publications, obtained over $75M in extramural research funding and two patents, and has trained over 35 postdoctoral associates and 25 doctoral students, about half with faculty/independent scientist positions in academia, government, and industry.
Previous appointments include director of the campus Neuroscience Program and interim dean of the College of Liberal Arts & Sciences. He serves or served on the National Academy of Sciences Council Executive Committee, National Research Council Governing Board and Executive Committee, NIH National Institute of Mental Health Advisory Council, Chan Zuckerberg Chicago Biohub Advisory Committee, provided Congressional testimony, and has past and current appointments on scientific advisory boards for companies and foundations with significant interests in genomics.
Selected awards and honors include Fellow and Founders Memorial Award (Entomological Society of America), Fellow and Distinguished Behaviorist (Animal Behavior Society), Distinguished Scientist Award (International Behavioral Genetics Society), Guggenheim Fellowship, Fulbright Fellowship, NIH Pioneer Award, Honorary Doctorate (Hebrew University), and the Wolf Prize in Agriculture. He is a member of the American Academy of Arts & Sciences, National Academy of Sciences, National Academy of Medicine, and American Philosophical Society.